DOCSLIB.ORG

Chromosomal Breakpoints in Primary Colon Cancer Cluster at Sites of Structural Variants in the Genome

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chromosomal Breakpoints in Primary Colon Cancer Cluster at Sites of Structural Variants in the Genome Research Article Chromosomal Breakpoints in Primary Colon Cancer Cluster at Sites of Structural Variants in the Genome Jordi Camps,1 Marian Grade,1,3 Quang Tri Nguyen,1 Patrick Ho¨rmann,1 Sandra Becker,1 Amanda B. Hummon,1 Virginia Rodriguez,2 Settara Chandrasekharappa,2 Yidong Chen,1 Michael J. Difilippantonio,1 Heinz Becker,3 B. Michael Ghadimi,3 and Thomas Ried1 1Genetics Branch, Center for Cancer Research, National Cancer Institute/NIH; 2Genome Technology Branch, National Human Genome Research Institute/NIH, Bethesda, Maryland; and 3Department of General and Visceral Surgery, University Medicine Go¨ttingen, Go¨ttingen, Germany Abstract 8q, 13, and 20q as well as losses of chromosomes 4q, 8p, 17p, and 18q (2). Genomic aberrations on chromosome 8 are common in colon cancer, and are associated with lymph node and distant Within the last decade, microarray technology has been metastases as well as with disease susceptibility. This extensively applied to survey the cellular transcriptome of common prompted us to generate a high-resolution map of genomic solid tumors, including colorectal cancer, and for colon cancers, imbalances of chromosome 8 in 51 primary colon carcinomas gene expression signatures were subsequently correlated with using a custom-designed genomic array consisting of a tiling clinical outcome (for reviews, see refs. 3–5). However, high- path of BAC clones. This analysis confirmed the dominant role resolution mapping of chromosomal copy number changes has of this chromosome. Unexpectedly, the position of the break- only recently been achieved using BAC or cDNA clone-based arrays points suggested colocalization with structural variants in the (6–10). human genome. In order to map these sites with increased Chromosome 8q is one of the most frequently gained resolution and to extend the analysis to the entire genome, chromosomal arms in colorectal cancers (2), and it is we analyzed a subset of these tumors (n = 32) by comparative conceivable that it contains more oncogenes than just the genomic hybridization on a 185K oligonucleotide array MYC oncogene, which maps to chromosome band 8q24.21. A potential role of chromosome 8q for the development of lymph platform. Our comprehensive map of the colon cancer genome confirmed recurrent and specific low-level copy number node metastases has been previously reported (11), and changes of chromosomes 7, 8, 13, 18, and 20, and unveiled overexpression of a gene, PRL-3, that maps to chromosome additional, novel sites of genomic imbalances including 8q24.3has been implied in the development of liver metastases amplification of a histone gene cluster on chromosome (12). Moreover, the 8q24 locus contains single nucleotide 6p21.1-21.33 and deletions on chromosome 4q34-35. The polymorphisms that are associated with an increased risk for systematic comparison of segments of copy number change the development of colon cancer (13–15). with gene expression profiles showed that genomic imbal- Recently, a new class of genetic variation among humans has ances directly affect average expression levels. Strikingly, we become recognized as a major source of genetic diversity. Termed observed a significant association of chromosomal break- structural variations, these polymorphisms can present themselves as copy number variants (CNV) and segmental duplications, points with structural variants in the human genome: 41% of all copy number changes occurred at sites of such copy which could be CNVs, but are not necessarily so (16–19). These À number variants (P < 2.2e 16). Such an association has not polymorphisms could induce chromosomal rearrangements (20). been previously described and reveals a yet underappreciated One of our previous analyses of chromosomal aberrations in cell plasticity of the colon cancer genome; it also points to lines established from different carcinomas indicated that genomic potential mechanisms for the induction of chromosomal copy number changes could be triggered by jumping trans- locations, many of which originated in the pericentromeric breakage in cancer cells. [Cancer Res 2008;68(5):1284–95] heterochromatin of several chromosomes (21). These regions frequently contain segmental duplications and other structural Introduction variants of the genome (22). Taken together, these data enticed us Colorectal cancer is the second leading cause of cancer death to systematically explore the genomic aberration profile and the in Europe and in the United States, with f300,000 new cases potential involvement of structural variants of the human genome and 200,000 deaths each year (1). Cytogenetic and molecular in the genesis of chromosomal aberrations in this common cancer. cytogenetic studies clearly established that the colorectal cancer We therefore established a high-resolution map of genomic copy genome is defined by a specific distribution of genomic imbalances, number changes in 51 primary colon carcinomas using compar- most prominently, gains of chromosomes and chromosome arms 7, ative genomic hybridization (CGH) on both a BAC-based genomic tiling array for chromosome 8 and, for a subset of those, using a 185K oligonucleotide platform for whole genome coverage. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). Requests for reprints: Thomas Ried, Genetics Branch, Center for Cancer Materials and Methods Research, National Cancer Institute/NIH, Building 50, Room 1408, 50 South Drive, Bethesda, MD 20892. Phone: 301-594-3118; Fax: 301-435-4428; E-mail: riedt@mail. nih.gov. Patients and Sample Collection I2008 American Association for Cancer Research. The 51 patients included in this study were diagnosed with primary doi:10.1158/0008-5472.CAN-07-2864 adenocarcinomas of the colon, and treated at the Department of General Cancer Res 2008; 68: (5). March 1, 2008 1284 www.aacrjournals.org Downloaded from cancerres.aacrjournals.org on September 30, 2021. © 2008 American Association for Cancer Research. Chromosomal Breakpoints Cluster at Copy Number Variants Surgery, University Medicine Go¨ttingen, Go¨ttingen, Germany. All patients immediately after surgery and stored on ice for inspection by an experienced received standardized surgery and histopathologic workup, and tumor pathologist. Consistent with standard procedures, only samples with a staging was based on WHO criteria (23). Twenty-five tumors were associated tumor cell content of at least 70% were included in this study. Biopsies of with lymph node metastases [International Union Against Cancer (UICC)- normal adjacent mucosa were collected from some patients when possible. III], whereas 26 tumors were not (UICC-II). Tumor samples were obtained Table 1 summarizes the clinical data and experimental setup. Table 1. Clinical information and experimental setup Patient code Histopathology Chromosome 8 Gene expression 185K oligonucleotide BAC microarray microarray microarray ÂÂ Â CC-P1 pT3a pN0 (0/17) M0 R0 G2 ÂÂ CC-P2 pT3 pN0 (0/19) M0 R0 G2 ÂÂ CC-P3pT 3 pN0 (0/29) M0 R0 G2 ÂÂ CC-P4 pT3a pN0 (0/31) M0 R0 G3 ÂÂ Â CC-P6 pT4 pN0 (0/17) M0 R0 G3 ( ) ÂÂ CC-P7 pT3 pN0 (0/25) M0 R0 G2 ÂÂ Â CC-P8 pT3 pN0 (0/44) M0 R0 G2 ÂÂ Â CC-P9 pT3b pN0 (0/31) M0 R0 G1-2 ÂÂ Â CC-P10 pT3b pN0 (0/20) M0 R0 G2 Â ÂÂ CC-P11 pT3a pN0 (0/21) M0 R0 G2 ( ) ÂÂ Â CC-P12 pT3 pN0 (0/27) M0 R0 G2 ÂÂ CC-P13pT 3b pN0 (0/39) M0 R0 G2 ÂÂ Â CC-P14 pT3 pN0 (0/23) M0 R0 G2 ÂÂ Â CC-P15 pT3 pN0 (0/31) M0 R0 G3 ÂÂ Â CC-P16 pT3 pN0 (0/15) M0 R0 G2 ÂÂ Â CC-P19 pT4 pN0 (0/57) M0 R0 G2 ÂÂ Â CC-P20 pT3b pN0 (0/28) M0 R0 G2 ÂÂ Â CC-P21 pT3b pN0 (0/24) M0 R0 G2 ÂÂ Â CC-P22 pT3 pN0 (0/15) M0 R0 G2 ÂÂ Â CC-P23pT 3 pN0 (0/21) M0 R0 G3 ÂÂ Â CC-P24 pT3 pN0 (0/17) M0 R0 G2 ÂÂ CC-P26 pT3 pN0 (0/20) M0 R0 G2 ÂÂ CC-P27 pT3 pN0 (0/26) M0 R0 G2 ÂÂ CC-P28 pT3 pN0 (0/20) M0 R0 G2 ÂÂ CC-P30 pT3b pN0 (0/35) M0 R0 G2 ÂÂ CC-P32 pT3a pN0 (0/23) M0 R0 G2 ÂÂ CC-P34 pT3 pN1 (2/17) M0 R0 G2 ÂÂ CC-P35 pT4 pN1 (2/51) M0 R0 G2 ÂÂ CC-P36 pT3 pN2 (15/42) M0 R0 G2 ÂÂ CC-P37 pT3 pN1 (1/25) M0 R0 G2 ÂÂ Â CC-P38 pT2 pN1 (1/23) M0 R0 G2-3 ÂÂ Â CC-P39 pT3c pN1 (1/28) M0 R0 G2 ÂÂ Â CC-P42 pT3a pN1 (1/2) M0 R0 G2 ÂÂ Â CC-P44 pT1-3 pN1 (2/26) M0 R0 G2 ÂÂ Â CC-P45 pT4 pN2 (4/36) M0 R0 G2 ÂÂ CC-P46 pT3b pN2 (8/16) M0 R0 G3 Â ÂÂ CC-P47 pT3 pN2 (12/13) M0 R0 G2 ( ) ÂÂ Â CC-P48 pT3a pN2 (5/23) M0 R0 G2 Â ÂÂ CC-P49 pT4 pN2 (9/21) M0 R0 G2 ( ) ÂÂ Â CC-P51 pT3c pN2 (4/23) M0 R0 G2 Â ÂÂ CC-P53pT 4 pN2 (11/26) M0 R0 G2 ( ) Â ÂÂ CC-P54 pT3 pN1 (3/22) M0 R0 G2 ( ) ÂÂ Â CC-P56 pT3b pN1 (2/20) M0 R0 G2 ÂÂ CC-P58 pT3 pN2 (1/32) M0 R0 G2 ÂÂ Â CC-P60 pT3 pN1 (2/24) M0 R0 G2 ÂÂ Â CC-P65 pT3 pN1 (2/22) M0 R0 G2-3 ÂÂ CC-P66 pT2 pN2 (4/20) M0 R0 G2 ÂÂ CC-P68 pT3c pN2 (12/22) M0 R0 G3 ÂÂ CC-P70 pT3 pN2 (12/21) M0 R0 G2 ÂÂ Â CC-P71 pT3 pN1 (1/18) M0 R0 G3 ÂÂ Â CC-P72 pT2 pN1 (2/18) M0 R0 G3 NOTE: (Â), not included.
Load more

Recommended publications
  • Amplification of 8Q21 in Breast Cancer Is Independent of MYC and Associated with Poor Patient Outcome
    Modern Pathology (2010) 23, 603–610 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 603 Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome Matthias Choschzick1, Paula Lassen1, Annette Lebeau1, Andreas Holger Marx1, Luigi Terracciano2, Uwe Heilenko¨tter3, Fritz Jaenicke4, Carsten Bokemeyer5, Jakob Izbicki6, Guido Sauter1 and Ronald Simon1 1Institute of Pathology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 2Institute of Pathology, University Hospital Basel, Basel, Switzerland; 3Department of Gynaecology, Hospital Itzehoe, Itzehoe, Germany; 4Department of Gynaecology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 5Department of Oncology, Hematology, Bone Marrow Transplantation with Section Pneumology, University Hospital Hamburg-Eppendorf, Hamburg, Germany and 6Department of Surgery, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany Copy number gains involving the long arm of chromosome 8, including high-level amplifications at 8q21 and 8q24, have been frequently reported in breast cancer. Although the role of the MYC gene as the driver of the 8q24 amplicon is well established, the significance of the 8q21 amplicon is less clear. The breast cancer cell line SK-BR-3 contains three separate 8q21 amplicons, the distal two of which correspond to putative target genes TPD52 and WWP1. To understand the effect of proximal 8q21 amplification on breast cancer phenotype and patient prognosis, we analyzed 8q21 copy number changes using fluorescence in situ hybridization (FISH) in a tissue microarray containing more than 2000 breast cancers. Amplification at 8q21 was found in 3% of tumors, and was associated with medullary type (Po0.03), high tumor grade (Po0.0001), high Ki67 labeling index (Po0.05), amplification of MYC (Po0.0001), HER2, MDM2, and CCND1 (Po0.05 each), as well as the total number of gene amplifications (Po0.0001).
    [Show full text]
  • Universidade Estadual De Campinas Instituto De Biologia
    UNIVERSIDADE ESTADUAL DE CAMPINAS INSTITUTO DE BIOLOGIA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA CAMPINAS 2016 1 VERÔNICA APARECIDA MONTEIRO SAIA CEREDA O PROTEOMA DO CORPO CALOSO DA ESQUIZOFRENIA THE PROTEOME OF THE CORPUS CALLOSUM IN SCHIZOPHRENIA Dissertação apresentada ao Instituto de Biologia da Universidade Estadual de Campinas como parte dos requisitos exigidos para a obtenção do Título de Mestra em Biologia Funcional e Molecular na área de concentração de Bioquímica. Dissertation presented to the Institute of Biology of the University of Campinas in partial fulfillment of the requirements for the degree of Master in Functional and Molecular Biology, in the area of Biochemistry. ESTE ARQUIVO DIGITAL CORRESPONDE À VERSÃO FINAL DA DISSERTAÇÃO DEFENDIDA PELA ALUNA VERÔNICA APARECIDA MONTEIRO SAIA CEREDA E ORIENTADA PELO DANIEL MARTINS-DE-SOUZA. Orientador: Daniel Martins-de-Souza CAMPINAS 2016 2 Agência(s) de fomento e nº(s) de processo(s): CNPq, 151787/2F2014-0 Ficha catalográfica Universidade Estadual de Campinas Biblioteca do Instituto de Biologia Mara Janaina de Oliveira - CRB 8/6972 Saia-Cereda, Verônica Aparecida Monteiro, 1988- Sa21p O proteoma do corpo caloso da esquizofrenia / Verônica Aparecida Monteiro Saia Cereda. – Campinas, SP : [s.n.], 2016. Orientador: Daniel Martins de Souza. Dissertação (mestrado) – Universidade Estadual de Campinas, Instituto de Biologia. 1. Esquizofrenia. 2. Espectrometria de massas. 3. Corpo caloso.
    [Show full text]
  • Manual Annotation and Analysis of the Defensin Gene Cluster in the C57BL
    BMC Genomics BioMed Central Research article Open Access Manual annotation and analysis of the defensin gene cluster in the C57BL/6J mouse reference genome Clara Amid*†1, Linda M Rehaume*†2, Kelly L Brown2,3, James GR Gilbert1, Gordon Dougan1, Robert EW Hancock2 and Jennifer L Harrow1 Address: 1Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK, 2University of British Columbia, Centre for Microbial Disease & Immunity Research, 2259 Lower Mall, Vancouver, BC, V6T 1Z4, Canada and 3Department of Rheumatology and Inflammation Research, Göteborg University, Guldhedsgatan 10, S-413 46 Göteborg, Sweden Email: Clara Amid* - [email protected]; Linda M Rehaume* - [email protected]; Kelly L Brown - [email protected]; James GR Gilbert - [email protected]; Gordon Dougan - [email protected]; Robert EW Hancock - [email protected]; Jennifer L Harrow - [email protected] * Corresponding authors †Equal contributors Published: 15 December 2009 Received: 15 May 2009 Accepted: 15 December 2009 BMC Genomics 2009, 10:606 doi:10.1186/1471-2164-10-606 This article is available from: http://www.biomedcentral.com/1471-2164/10/606 © 2009 Amid et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Host defense peptides are a critical component of the innate immune system. Human alpha- and beta-defensin genes are subject to copy number variation (CNV) and historically the organization of mouse alpha-defensin genes has been poorly defined.
    [Show full text]
  • Mapping DNA Structural Variation in Dogs
    Downloaded from genome.cshlp.org on October 3, 2021 - Published by Cold Spring Harbor Laboratory Press Resource Mapping DNA structural variation in dogs Wei-Kang Chen,1,4 Joshua D. Swartz,1,4,5 Laura J. Rush,2 and Carlos E. Alvarez1,3,6 1Center for Molecular and Human Genetics, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio 43205, USA; 2Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, USA; 3Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA DNA structural variation (SV) comprises a major portion of genetic diversity, but its biological impact is unclear. We propose that the genetic history and extraordinary phenotypic variation of dogs make them an ideal mammal in which to study the effects of SV on biology and disease. The hundreds of existing dog breeds were created by selection of extreme morphological and behavioral traits. And along with those traits, each breed carries increased risk for different diseases. We used array CGH to create the first map of DNA copy number variation (CNV) or SV in dogs. The extent of this variation, and some of the gene classes affected, are similar to those of mice and humans. Most canine CNVs affect genes, including disease and candidate disease genes, and are thus likely to be functional. We identified many CNVs that may be breed or breed class specific. Cluster analysis of CNV regions showed that dog breeds tend to group according to breed classes. Our combined findings suggest many CNVs are (1) in linkage disequilibrium with flanking sequence, and (2) associated with breed-specific traits.
    [Show full text]
  • Epigenome-Wide Exploratory Study of Monozygotic Twins Suggests Differentially Methylated Regions to Associate with Hand Grip Strength
    Biogerontology (2019) 20:627–647 https://doi.org/10.1007/s10522-019-09818-1 (0123456789().,-volV)( 0123456789().,-volV) RESEARCH ARTICLE Epigenome-wide exploratory study of monozygotic twins suggests differentially methylated regions to associate with hand grip strength Mette Soerensen . Weilong Li . Birgit Debrabant . Marianne Nygaard . Jonas Mengel-From . Morten Frost . Kaare Christensen . Lene Christiansen . Qihua Tan Received: 15 April 2019 / Accepted: 24 June 2019 / Published online: 28 June 2019 Ó The Author(s) 2019 Abstract Hand grip strength is a measure of mus- significant CpG sites or pathways were found, how- cular strength and is used to study age-related loss of ever two of the suggestive top CpG sites were mapped physical capacity. In order to explore the biological to the COL6A1 and CACNA1B genes, known to be mechanisms that influence hand grip strength varia- related to muscular dysfunction. By investigating tion, an epigenome-wide association study (EWAS) of genomic regions using the comb-p algorithm, several hand grip strength in 672 middle-aged and elderly differentially methylated regions in regulatory monozygotic twins (age 55–90 years) was performed, domains were identified as significantly associated to using both individual and twin pair level analyses, the hand grip strength, and pathway analyses of these latter controlling the influence of genetic variation. regions revealed significant pathways related to the Moreover, as measurements of hand grip strength immune system, autoimmune disorders, including performed over 8 years were available in the elderly diabetes type 1 and viral myocarditis, as well as twins (age 73–90 at intake), a longitudinal EWAS was negative regulation of cell differentiation.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer Et Al
    US 20120264.634A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0264.634 A1 Amersdorfer et al. (43) Pub. Date: Oct. 18, 2012 (54) MARKER SEQUENCES FOR PANCREATIC Publication Classification CANCER DISEASES, PANCREATIC (51) Int. Cl. CARCINOMIA AND USE THEREOF C40B 30/04 (2006.01) GOIN 2L/64 (2006.01) (75) Inventors: Peter Amersdorfer, Graz (AT); GOIN 27/72 (2006.01) Annabel Höpfner, Dortmund (DE); C07K I4/435 (2006.01) Angelika Lueking, Bochum (DE) C40B 40/06 (2006.01) C40B 40/10 (2006.01) CI2N 5/09 (2010.01) (73) Assignee: PROTAGEN Aktiengesellschaft, C7H 2L/04 (2006.01) Dortmund (DE) GOIN 33/574 (2006.01) GOIN 27/62 (2006.01) (21) Appl. No.: 13/498,964 (52) U.S. Cl. ........... 506/9:436/501; 435/6.14; 435/7.92; 506/16:506/18: 435/2:536/23.1; 530/350 (22) PCT Filed: Sep. 29, 2010 (57) ABSTRACT The present invention relates to novel marker sequences for (86). PCT No.: PCT/EP2010/064510 pancreatic cancer diseases, pancreatic carcinoma and the diagnostic use thereof together with a method for Screening of S371 (c)(1), potential active Substances for pancreatic cancer diseases, (2), (4) Date: Jun. 22, 2012 pancreatic carcinoma by means of these marker sequences. Furthermore, the invention relates to a diagnostic device con (30) Foreign Application Priority Data taining Such marker sequences for pancreatic cancer diseases, pancreatic carcinoma, in particular a protein biochip and the Sep. 29, 2009 (EP) .................................. O9171690.2 use thereof. Patent Application Publication Oct. 18, 2012 US 2012/0264.634 A1 US 2012/0264.634 A1 Oct.
    [Show full text]
  • Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected]
    University of South Florida Scholar Commons Graduate Theses and Dissertations Graduate School July 2017 Role of Amylase in Ovarian Cancer Mai Mohamed University of South Florida, [email protected] Follow this and additional works at: http://scholarcommons.usf.edu/etd Part of the Pathology Commons Scholar Commons Citation Mohamed, Mai, "Role of Amylase in Ovarian Cancer" (2017). Graduate Theses and Dissertations. http://scholarcommons.usf.edu/etd/6907 This Dissertation is brought to you for free and open access by the Graduate School at Scholar Commons. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. Role of Amylase in Ovarian Cancer by Mai Mohamed A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Pathology and Cell Biology Morsani College of Medicine University of South Florida Major Professor: Patricia Kruk, Ph.D. Paula C. Bickford, Ph.D. Meera Nanjundan, Ph.D. Marzenna Wiranowska, Ph.D. Lauri Wright, Ph.D. Date of Approval: June 29, 2017 Keywords: ovarian cancer, amylase, computational analyses, glycocalyx, cellular invasion Copyright © 2017, Mai Mohamed Dedication This dissertation is dedicated to my parents, Ahmed and Fatma, who have always stressed the importance of education, and, throughout my education, have been my strongest source of encouragement and support. They always believed in me and I am eternally grateful to them. I would also like to thank my brothers, Mohamed and Hussien, and my sister, Mariam. I would also like to thank my husband, Ahmed.
    [Show full text]
  • Defensin Beta 5 Human Protein – AR31146PU-N | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for AR31146PU-N Defensin beta 5 Human Protein Product data: Product Type: Recombinant Proteins Description: Defensin beta 5 human recombinant protein, 20 µg Species: Human Expression Host: E. coli Predicted MW: 5.8 kDa Purity: >98% by SDS-PAGE gel and HPLC analyses Buffer: Presentation State: Purified State: Lyophilized (sterile filtered) protein Buffer System: None Preservative: None Stabilizer: None Endotoxin: < 0.1 ng per μg (1EU/μg) Reconstitution Method: Restore in Water to a concentration of 0.1-1.0 mg/ml. Do not vortex. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to - 80°C. Preparation: Lyophilized (sterile filtered) protein Protein Description: Recombinant Human BD-5 is a 5.8 kDa protein containing 51 amino acid residues. Note: Centrifuge vial before opening. Storage: Store lyophilized at 2-8°C for 6 months or at -20°C long term. After reconstitution store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C long term. Avoid repeated freezing and thawing. Stability: Shelf life: one year from despatch. RefSeq: NP_689463 Locus ID: 245908 UniProt ID: Q8NG35, A0A0K0K1I4 Cytogenetics: 8p23.1 This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Defensin beta 5 Human Protein – AR31146PU-N Synonyms: BD-5; DEFB-5; DEFB105 Summary: Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils.
    [Show full text]
  • Análise Correlacional Entre a Expressão Dos Fatores De Splicing E a Ocorrência De Splicing Alternativo Em Tecidos Humanos E De Camundongos
    ANÁLISE CORRELACIONAL ENTRE A EXPRESSÃO DOS FATORES DE SPLICING E A OCORRÊNCIA DE SPLICING ALTERNATIVO EM TECIDOS HUMANOS E DE CAMUNDONGOS JULIO CÉSAR NUNES Dissertação apresentada à Fundação Antônio Prudente para a obtenção do título de Mestre em Ciências Área de Concentração: Oncologia Orientador: Dr. Sandro José de Souza São Paulo 2008 Livros Grátis http://www.livrosgratis.com.br Milhares de livros grátis para download. FICHA CATALOGRÁFICA Preparada pela Biblioteca da Fundação Antônio Prudente Nunes, Julio César Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos / Julio César Nunes – São Paulo, 2008. 79p. Dissertação (Mestrado) - Fundação Antônio Prudente. Curso de Pós-Graduação em Ciências - Área de concentração: Oncologia. Orientador: Sandro José Souza Descritores: 1. SPLICING ALTERNATIVO 2. BIOLOGIA MOLECULAR COMPUTACIONAL 3. CÂNCER 4. GENOMICA. AGRADECIMENTOS Agradeço à FAPESP e CAPES pela bolsa de Mestrado. Ao Sandro José de Souza agradeço toda orientação e conhecimento oferecido. Meus especiais agradecimentos ao Pedro Alexandre Favoretto Galante que dedicou atenção a minha formação no processo de Pós-Graduação na Fundação Antônio Prudente, bem como pela sua oficiosa co-orientação ao projeto de pesquisa. À grande família e amigos pela dedicação e incentivo a minha formação acadêmica. À Fundação Antônio Prudente, Hospital do Câncer e Instituto Ludwig de Pesquisa sobre o Câncer dedico os meus nobres agradecimentos finais. RESUMO Nunes JC. Análise correlacional entre a expressão dos fatores de splicing e a ocorrência de splicing alternativo em tecidos humanos e de camundongos. São Paulo; 2007. [Dissertacão de Mestrado - Fundação Antônio Prudente] Splicing alternativo desempenha uma significante função no aumento da complexidade genômica, produzindo um extenso número de mRNA e isoformas protéicas.
    [Show full text]
  • Histone-Related Genes Are Hypermethylated in Lung Cancer
    Published OnlineFirst October 1, 2019; DOI: 10.1158/0008-5472.CAN-19-1019 Cancer Genome and Epigenome Research Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated HIST1H4F Could Serve as a Pan-Cancer Biomarker Shihua Dong1,Wei Li1, Lin Wang2, Jie Hu3,Yuanlin Song3, Baolong Zhang1, Xiaoguang Ren1, Shimeng Ji3, Jin Li1, Peng Xu1, Ying Liang1, Gang Chen4, Jia-Tao Lou2, and Wenqiang Yu1 Abstract Lung cancer is the leading cause of cancer-related deaths lated in all 17 tumor types from TCGA datasets (n ¼ 7,344), worldwide. Cytologic examination is the current "gold stan- which was further validated in nine different types of cancer dard" for lung cancer diagnosis, however, this has low sensi- (n ¼ 243). These results demonstrate that HIST1H4F can tivity. Here, we identified a typical methylation signature of function as a universal-cancer-only methylation (UCOM) histone genes in lung cancer by whole-genome DNA methyl- marker, which may aid in understanding general tumorigen- ation analysis, which was validated by The Cancer Genome esis and improve screening for early cancer diagnosis. Atlas (TCGA) lung cancer cohort (n ¼ 907) and was further confirmed in 265 bronchoalveolar lavage fluid samples with Significance: These findings identify a new biomarker for specificity and sensitivity of 96.7% and 87.0%, respectively. cancer detection and show that hypermethylation of histone- More importantly, HIST1H4F was universally hypermethy- related genes seems to persist across cancers. Introduction to its low specificity, LDCT is far from satisfactory as a screening tool for clinical application, similar to other currently used cancer Lung cancer is one of the most common malignant tumors and biomarkers, such as carcinoembryonic antigen (CEA), neuron- the leading cause of cancer-related deaths worldwide (1, 2).
    [Show full text]
  • The Human Isoform of RNA Polymerase II Subunit Hrpb11bα Specifically Interacts with Transcription Factor ATF4
    International Journal of Molecular Sciences Article The Human Isoform of RNA Polymerase II Subunit hRPB11bα Specifically Interacts with Transcription Factor ATF4 Sergey A. Proshkin 1,2, Elena K. Shematorova 1 and George V. Shpakovski 1,* 1 Laboratory of Mechanisms of Gene Expression, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia; [email protected] (S.A.P.); [email protected] (E.K.S.) 2 Engelhardt Institute of Molecular Biology, Center for Precision Genome Editing and Genetic Technologies for Biomedicine, 119991 Moscow, Russia * Correspondence: [email protected]; Tel.: +7-495-3306583; Fax: +7-495-3357103 Received: 25 November 2019; Accepted: 22 December 2019; Published: 24 December 2019 Abstract: Rpb11 subunit of RNA polymerase II of Eukaryotes is related to N-terminal domain of eubacterial α subunit and forms a complex with Rpb3 subunit analogous to prokaryotic α2 homodimer, which is involved in RNA polymerase assembly and promoter recognition. In humans, a POLR2J gene family has been identified that potentially encodes several hRPB11 proteins differing mainly in their short C-terminal regions. The functions of the different human specific isoforms are still mainly unknown. To further characterize the minor human specific isoform of RNA polymerase II subunit hRPB11bα, the only one from hRPB11 (POLR2J) homologues that can replace its yeast counterpart in vivo, we used it as bait in a yeast two-hybrid screening of a human fetal brain cDNA library. By this analysis and subsequent co-purification assay in vitro, we identified transcription factor ATF4 as a prominent partner of the minor RNA polymerase II (RNAP II) subunit hRPB11bα.
    [Show full text]
  • Precise, Pan-Cancer Discovery of Gene Fusions Reveals a Signature Of
    bioRxiv preprint doi: https://doi.org/10.1101/178061; this version posted August 18, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Precise, pan-cancer discovery of gene fusions reveals a signature of selection in primary 2 tumors 3 4 Donald Eric Freeman1,3,Gillian Lee Hsieh1, Jonathan Michael Howard1, Erik Lehnert2, Julia 5 Salzman1,3,4* 6 7 Author affiliation 8 1Stanford University Department of Biochemistry, 279 Campus Drive, Stanford, CA 94305 9 2Seven Bridges Genomics, 1 Main Street, Suite 500, Cambridge MA 02142 10 3Stanford University Department of Biomedical Data Science, Stanford, CA 94305-5456 11 4Stanford Cancer Institute, Stanford, CA 94305 12 13 *Corresponding author [email protected] 14 15 Short Abstract: 16 The eXtent to which gene fusions function as drivers of cancer remains a critical open question 17 in cancer biology. In principle, transcriptome sequencing provided by The Cancer Genome 18 Atlas (TCGA) enables unbiased discovery of gene fusions and post-analysis that informs the 19 answer to this question. To date, such an analysis has been impossible because of 20 performance limitations in fusion detection algorithms. By engineering a new, more precise, 21 algorithm and statistical approaches to post-analysis of fusions called in TCGA data, we report 22 new recurrent gene fusions, including those that could be druggable; new candidate pan-cancer 23 oncogenes based on their profiles in fusions; and prevalent, previously overlooked, candidate 24 oncogenic gene fusions in ovarian cancer, a disease with minimal treatment advances in recent 25 decades.
    [Show full text]